25 February 2026
ViiV Healthcare: Lotivibart Shows 94% Viral Suppression in Long-Acting HIV Treatment
Lotivibart, combined with CAB LA, maintained viral suppression in 94% of participants. Study progresses to test twice-yearly dosing. Well-tolerated with fewer adverse events in IV group.
